Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset
Project # Project Title Research Focus Area Research Program Administering IC Institution(s) Investigator(s) Location(s) Year Awarded
1R61CA280979-01
Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors Clinical Research in Pain Management Advancing Health Equity in Pain Management NCI EMORY UNIVERSITY IM, EUN-OK (contact); CHEE, WONSHIK Atlanta, GA 2022
NOFO Title: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)
NOFO Number: RFA-NS-22-037
Summary:

Asian American women who have survived breast cancer and who also have depression are less likely to receive adequate pain treatment due to cultural stigma attached to breast cancer, cultural attitudes about living with pain and symptoms, and language barriers. This project will use a personalizable, technology-based approach to treat cancer pain and depression in Japanese American, Chinese American, and Korean American women who have survived breast cancer. The intervention will accommodate flexibility, accessibility, and anonymity: three factors that have historically hindered effective pain management for this population of breast cancer survivors.
1R21DE032531-01
Long-term Opioid Therapy, Depression, and Suicide Mortality Risk in Patients with Head and Neck Cancer Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDCR DUKE UNIVERSITY OSAZUWA-PETERS, NOSAYABA Durham, NC 2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011
Summary:

It is unclear if long-term use of opioids by head and neck cancer patients affects risk for depression, which is higher in this population compared to people without cancer. This knowledge could inform interventions such as increased opioid prescription safety or alternative pain management approaches and could thus help reduce the risk for depression-related outcomes. This project will use data from a national cancer database linked to Medicare claims and a Veterans Administration database to determine whether people with head and neck cancer that take opioid medications for more than 90 days have increased risk for new-onset or worsening depression or suicide death.
1UG3DA057853-01
Naltrexone Transdermal Patch - An Accessible, Patient-Focused Option to Treat OUD Relapse Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA LIBERO PHARMA LIMITED GARDINER, ANDREW Edinburgh, United Kingdom 2022
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3)
NOFO Number: PAR-20-092​
Summary:

Naltrexone is the only medication approved by the U.S. Food and Drug Administration to prevent relapse from opioid use disorder. This medication remains underused because it must be injected into muscle by a nurse and is relatively expensive. This project will develop and test a novel naltrexone skin patch that is easier to use, more comfortable, and inexpensive.
1R01DA057608-01
Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology Translation of Research to Practice for the Treatment of Opioid Addiction Improving Delivery of Healthcare Services for Polysubstance Use NIDA FRIENDS RESEARCH INSTITUTE, INC. MITCHELL, SHANNON GWIN Baltimore, MD 2022
NOFO Title: HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)
NOFO Number: DA22-047
Summary:

Although methadone is an effective treatment for opioid use disorder, many individuals drop out of treatment, putting them at risk of relapse and overdose. One of the factors associated with poor retention in methadone treatment is concurrent cocaine use. There is currently no effective medical treatment for cocaine use disorder. However, contingency management, in which individuals receive tangible rewards for desired behaviors such as abstinence, has been shown to be effective for cocaine use. This project will test the value of a digital therapy app, DynamiCare Health Contingency Management, in methadone treatment programs to promote treatment for polysubstance use.
1R24DA051974-01A1
Enhancing Effectiveness Research on Recovery Housing for Persons Prescribed Medication for Opioid Use Disorder Translation of Research to Practice for the Treatment of Opioid Addiction Recovery Research Networks NIDA PUBLIC HEALTH INSTITUTE MERICLE, AMY ADALE (contact); MASSON, CARMEN L Oakland, CA 2022
NOFO Title: HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional)
NOFO Number: RFA-DA-22-043
Summary:

Safe and stable housing is widely considered to be critical to recovery from alcohol and drug use disorders. Therefore, providing dedicated safe and substance-free housing options for individuals in recovery (recovery housing) may be an essential component of a comprehensive response to the current opioid crisis. However, there is limited evidence about effective recovery housing practices for individuals choosing treatment with medications for opioid use disorders as part of their path to recovery. This project will enhance the infrastructure necessary to study the effectiveness of recovery housing for these individuals. It will develop a national multi-stakeholder network, host webinars for researchers and recovery housing providers, and support mentored pilot studies for new researchers seeking to study recovery housing.
1R61DA057675-01
Using System Dynamics Modeling to Foster Real-Time Connections to Care Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA YALE UNIVERSITY HECKMANN, REBEKAH (contact); S SABOUNCHI, NASIM New Haven, CT 2022
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051
Summary:

First responders prevent many overdose deaths by providing life-saving resuscitation and giving naloxone to reverse an opioid overdose. This project will use a modeling approach to assess the impact of Good Samaritan Laws that protect people from certain criminal penalties if they call 911 to save an overdose victim by giving naloxone on overdose mortality. This research will develop and test a novel, scalable, telehealth platform that can be used at the time of an opioid overdose to link patients with access to medication for opioid use disorder, harm reduction services, and recovery support. The research will be informed by patient-outcome data.
1R21AT012431-01
Psychosocial Risk Factors for Chronic Pain: Characterizing Brain and Genetic Pathways and Variation Across Understudied Populations Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NCCIH DARTMOUTH COLLEGE WAGER, TOR D Hanover, NH 2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011
Summary:

Fifty million Americans experience chronic pain, including about 25 million who report pain that substantially interferes with daily activities and reduces quality of life. Mental health problems, including depression, anxiety, and post-traumatic stress disorder, increase risk for severe chronic pain. This project will use genetic data, information about observable characteristics (phenotypic data), and neuroimaging data from three large databases to identify psychosocial factors that predict chronic pain, assess differences across diverse U.S. populations, and determine whether risk profiles predict post-surgical chronic pain.
1R21DE032584-01
Identifying Chronic Pain Phenotypes and Treatment Disparities in Adults with Cerebral Palsy Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDCR UNIVERSITY OF MICHIGAN PETERSON, MARK D Ann Arbor, MI 2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011
Summary:

Cerebral palsy is the most common physical disability in children. Those who have this condition experience pain throughout their lives. Although opioids are generally not recommended, many adults with cerebral palsy are prescribed them for pain. This project will assess the incidence of chronic pain conditions in adults with and without cerebral palsy as well as measure opioid treatment-related health outcomes in adults with cerebral palsy. This research will also evaluate pain treatment disparities related to race/ethnicity and insurance coverage using national medical claims databases.
1U01DA057846-01
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA VIRGINIA COMMONWEALTH UNIVERSITY BJORK, JAMES M; ARIAS, ALBERT JOSEPH Richmond, VA 2022
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01)
NOFO Number: PAR-19-327
Summary:

Currently no medications are approved by the U.S. Food and Drug Administration to treat cocaine use disorder, which compromises cognitive function associated with achieving goals such as working memory, the ability to update information, and mental flexibility. This project will test whether  stimulating dopamine activity in the brain with the drug rotigotine (approved to treat Parkinson’s disease) is effective for treating cocaine use disorder. Past research has also shown that rotigotine can improve nerve cell and cognitive function in Alzheimer’s disease. This project will conduct a clinical trial to test whether treatment with rotigotine combined with cognitive behavioral therapy can reduce cocaine use in people with cocaine use disorder.
1R34DA057678-01
Adaption of the STAIR-NT Trauma Intervention for Polysubstance Populations Translation of Research to Practice for the Treatment of Opioid Addiction Improving Delivery of Healthcare Services for Polysubstance Use NIDA NEW YORK UNIVERSITY SCHOOL OF MEDICINE BUNTING, AMANDA M (contact); RENN, TANYA RAE New York, NY 2022
NOFO Title: HEAL Initiative: Pilot & Feasibility Trials to Improve Prevention and Treatment Service Delivery for Polysubstance Use (R34 Clinical Trial Optional)
NOFO Number: DA22-048
Summary:

Compared to people who use only one type of drug, people who use combinations of drugs, such as opioids and stimulants, are more likely to have histories of childhood trauma, including post-traumatic stress disorder (PTSD). This project will adapt an existing PTSD intervention, Skills Training in Affective and Interpersonal Regulation with Narrative Therapy, to treat individuals with polysubstance use. This research will be piloted in a methadone maintenance treatment program to assess feasibility and acceptability. If successful, the findings will lay the groundwork for a large-scale clinical trial.
1R34DA057662-01
Development of an Integrated Intervention Involving Recovery Coaching and Cognitive Behavioral Therapy for Opioid Use Disorder Translation of Research to Practice for the Treatment of Opioid Addiction Recovery Research Networks NIDA CLEMSON UNIVERSITY LITWIN, ALAIN HARRIS (contact); HEO, MOONSEONG Clemson, SC 2022
NOFO Title: HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional)
NOFO Number: RFA-DA-22-034
Summary:

Many people intending to take medications for opioid use disorder, including buprenorphine, as part of their recovery pathway do not stay in treatment long enough to reduce risk for overdose. These individuals also often continue to use one or more other drugs during treatment, which may further raise their overdose risk. This project will develop and conduct a preliminary test of an innovative integrated intervention that combines buprenorphine treatment with recovery coaching and online cognitive behavioral therapy. This research will assess whether the approach reduces drug use during buprenorphine treatment and helps people stay in treatment longer.
1R61AT012421-01
Integrative Training Program for Pediatric Sickle Cell Pain Clinical Research in Pain Management Advancing Health Equity in Pain Management NCCIH EMORY UNIVERSITY SIL, SOUMITRI Atlanta, GA 2022
NOFO Title: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)
NOFO Number: RFA-NS-22-037
Summary:

Sickle cell disease is an inherited blood disorder affecting about 100,000 Americans and more than 20 million people worldwide. It is caused by a mutation in the gene for beta-globin that results in the characteristic sickled shape of red blood cells, life-long severe pain, and shortened lifespan. Optimal treatment of  chronic pain from the condition targets psychological factors contributing to pain, such as pain-related anxiety, fear of movement, and depression. This project will interact with patients and their families to revise and test an existing mind–body and behavioral health treatment tool to target the unique needs and preferences of people managing chronic sickle cell disease pain.
1R21DE032583-01
Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDCR VIRGINIA COMMONWEALTH UNIVERSITY VALRIE, CECELIA R (contact); MCGEE, REGINALD Richmond, VA 2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011
Summary:

Sickle cell disease is an inherited blood disorder affecting about 100,000 Americans and more than 20 million people worldwide. It is caused by a mutation in the gene for beta-globin that results in the characteristic sickled shape of red blood cells, life-long severe pain, and shortened lifespan. Sickle cell disease pain episodes are usually unanticipated, making it hard for people with the condition to manage their pain and putting them at risk for increased use of opioids and poor health outcomes. This project will use existing real-time health data to identify factors that can predict onset, severity, and worsening of daily pain in children with sickle cell disease.
2R44DA050358-02A1
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders Cross-Cutting Research Small Business Programs NIDA MINDLIGHT, LLC SCHIFFER, FREDRIC (contact); TEICHER, MARTIN H Newton, MA 2022
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

This project will refine an experimental non-invasive light therapy to create an effective, safe, convenient, and affordable method for treating opioid use disorder. This research will test whether a short treatment of near infra-red light administered through the skull can reduce drug use, relapse, and craving, and improve overall function in people with opioid use disorder. If effective, the findings could support a path toward commercialization of this new treatment.
1R01DA057672-01
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness Translation of Research to Practice for the Treatment of Opioid Addiction Improving Delivery of Healthcare Services for Polysubstance Use NIDA YALE UNIVERSITY MCNEIL, RYAN (contact); KNIGHT, KELLY RAY New Haven, CT 2022
NOFO Title: HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)
NOFO Number: DA22-047
Summary:

Compared to people with stable housing, individuals experiencing homelessness are more likely to use both fentanyl and stimulants and experience drug-related harms. This project will examine fentanyl-stimulant polysubstance use patterns and how they evolve over time in response to changes to housing status. It will also assess use of overdose prevention and substance use disorder treatment interventions in homeless individuals who use both fentanyl and stimulants, including how polysubstance use patterns shape their risk of overdose over time. This research will also interact with community stakeholders toward translating the findings into future research, policy, and program recommendations.
1R24DA057632-01
Collaborative Hub for Emerging Adult Recovery Research (CHEARR) Translation of Research to Practice for the Treatment of Opioid Addiction Recovery Research Networks NIDA UNIVERSITY OF CONNECTICUT SCH OF MED/DNT ZAJAC, KRISTYN Farmington, CT 2022
NOFO Title: HEAL Initiative: Research Networks for the Study of Recovery Support Services for Persons Treated with Medications for Opioid Use Disorder (R24 Clinical Trial Optional)
NOFO Number: RFA-DA-22-043
Summary:

The opioid crisis has been particularly devastating to adolescents and young adults between 16 and 25 years old. Recovery support services in community settings can help these individuals who take medications for opioid use disorder find a path to recovery. This project will develop a network of advanced researchers, recovery support specialists, adolescents and young adults in recovery, and other key community stakeholders to help rapidly advance the science of recovery support services. This research will focus in particular on continuing care services specialized for adolescents and young adults who currently take or who have taken medications for opioid use disorder.
1R61DA057660-01
Fatal Overdose Review Teams – Research to Enhance Surveillance Systems (FORTRESS) Cross-Cutting Research Translating Data 2 Action to Prevent Overdose NIDA INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS AALSMA, MATTHEW (contact); RAY, BRADLEY ; REDA, KHAIRI Indianapolis, IN 2022
NOFO Title: HEAL Initiative: HEAL Data2Action Innovation Projects (R61/R33 Clinical Trial Optional)
NOFO Number: RFA-DA-22-051
Summary:

Overdose fatality review teams review cases of overdose deaths to identify system gaps and innovative prevention and intervention strategies. With the rise in overdose deaths, these multidisciplinary teams require more timely population-level data to inform their recommendations. This project will develop the Overdose Touchpoints Dashboard that uses real-time data and records from multiple sources to help visualize common “overdose touchpoints” for harm reduction services and treatment opportunities. This research will compare use of the dashboard to standard overdose fatality review practices. The project will assess multiple aspects related to use of the dashboard, including process, staff attitudes, implementation successes, and usability.
1R61NR020845-01
Equity Using Interventions for Pain and Depression (EQUIPD) Clinical Research in Pain Management Advancing Health Equity in Pain Management NINR INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS MATTHIAS, MARIANNE Indianapolis, IN 2022
NOFO Title: HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required)
NOFO Number: RFA-NS-22-037
Summary:

Opioid overdose deaths disproportionately affect Black individuals in the United States. While the use of complementary and integrative pain treatments is effective and widely recommended, Black pain patients (especially those who also have depression) face barriers to the use of these approaches. This project will refine, test, and prepare to implement a novel approach to overcoming these treatment barriers. The research will partner with and empower Black patients to find safe, effective pain treatments that best match their values, preferences, and lifestyles.
1R21AT012430-01
Pain Management Strategies, Associated Psychological Variables, and Outcomes in Critical Limb Ischemia Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDCR YALE UNIVERSITY SMOLDEREN, KIM GERMAINE (contact); MENA-HURTADO, CARLOS New Haven, CT 2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011
Summary:

Critical limb ischemia is the most severe form of peripheral artery disease, is very painful, and can lead to amputation and even death. Most patients with this condition live with chronic pain, but comprehensive and effective treatment is lacking. This project will use existing data from three databases to study medical pain management approaches used over time by individuals with critical limb ischemia – toward creating an integrated, patient-centered, and multimodal pain management approach for this condition.
1U01DA056240-01
IND-Enabling Program for a Long-Acting Anti-Methamphetamine Monoclonal Antibody for Treating Methamphetamine Use Disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA INTERVEXION THERAPEUTICS, LLC STEVENS, MISTY WARD Little Rock, AR 2022
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01)
NOFO Number: PAR-19-327
Summary:

There are currently no medications approved by the U.S. Food and Drug Administration to treat methamphetamine use disorder, even though risky patterns of methamphetamine use and overdose deaths have increased in recent years. Research using animal models shows that immune molecules that latch onto methamphetamine (anti-methamphetamine antibodies) show promise in blocking the effects of the drug. This project aims to identify a long-acting monoclonal antibody targeted to methamphetamine and conduct development and safety studies to prepare for future testing of the antibody treatment in humans.
1R01DA057443-01
Peer-Delivered, Behavioral Activation Intervention to Improve Polysubstance Use and Retention in Mobile Telemedicine OUD Treatment in an Underserved, Rural Area Translation of Research to Practice for the Treatment of Opioid Addiction Improving Delivery of Healthcare Services for Polysubstance Use NIDA UNIVERSITY OF MARYLAND, COLLEGE PARK MAGIDSON, JESSICA F (contact); KATTAKUZHY, SARAH M College Park, MD 2022
NOFO Title: HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01 Clinical Trial Optional)
NOFO Number: DA22-047
Summary:

Polysubstance use, especially use of both opioids and stimulants, is compounding the already devastating effects of the opioid crisis in underserved rural areas. This project builds on a previously established treatment model for opioid use disorder that uses telehealth and mobile treatment units, which seeks to engage people in activities they enjoy, to help them avoid negative behaviors such as drug use. This research will evaluate the effectiveness of a behavioral treatment approach delivered by peer recovery support specialists in rural areas and using mobile treatment units. The project will measure the intervention’s effect on treatment retention and polysubstance use – as well as evaluate the intervention’s feasibility, acceptability, adoption, and economic value.
1R34DA057604-01
Planning Grant for a Multi-Site Trial to Examine the Effectiveness of Recovery Community Centers Serving Black Communities to Support Persons Using Medications for Opioid Use Disorder Translation of Research to Practice for the Treatment of Opioid Addiction Recovery Research Networks NIDA Massachusetts General Hospital HOEPPNER, BETTINA B (contact); KELLY, JOHN F Boston, MA 2022
NOFO Title: HEAL Initiative: Planning Grants for Efficacy or Effectiveness Trials of Recovery Support Services for Individuals Treated with Medications for Opioid Use Disorder (R34 Clinical Trial Optional)
NOFO Number: RFA-DA-22-034
Summary:

People who take medications for opioid use disorder as part of their recovery pathway need to take these medications for extended periods of time to reduce risk of overdose. Recovery community centers, which provide a range of recovery-oriented and peer-delivered services in a welcoming environment, may be an important asset for these individuals. This project joins two recovery community centers that serve Black communities with an academic research team to inform the design of a rigorous, large-scale clinical trial to determine if clinical referral to recovery community centers improves long-term recovery outcomes.
3R01MH128904-02S1
Supporting Treatment Access and Recovery for Co-Occurring Opioid Use and Mental Health Disorders (STAR-COD) Cross-Cutting Research Increasing Participant Diversity, Inclusion, and Engagement in HEAL Research NIMH UNIV OF MASSACHUSETTS MED SCH WORCESTER SMELSON, DAVID A (contact); GONZALEZ, GERARDO ; LI, WENJUN ; OLMSTEAD, TODD ALDEN Worcester, MA 2022
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
NOFO Number: NOT-NS-22-066
Summary:

Black/African American and Hispanic/Latino individuals suffer a disproportionate burden of co-occurring substance use and mental illness, in part due to reduced access to culturally responsive quality healthcare, compared to other racial/ethnic groups. In addition, Black/African American and Hispanic/Latino individuals are not well represented in clinical trials that could help reduce these health disparities. This research aims to improve the recruitment of Black/African American and Hispanic/Latino individuals to participate in clinical research related to co-occurring substance use and mental illness. The project will conduct community engagement and community-based participatory research, establishing a bidirectional partnership between researchers and community members.
1R21DE032532-01
Secondary Analysis and Integration of Existing Data Related to Chronic Orofacial Pain and Placebo Effects Cross-Cutting Research Leveraging Existing and Real-Time Opioid and Pain Management Data NIDCR UNIVERSITY OF MARYLAND, BALTIMORE COLLOCA, LUANA (contact); DORSEY, SUSAN G Baltimore, MD 2022
NOFO Title: HEAL Initiative: Secondary Analysis and Integration of Existing Data Related to Acute and Chronic Pain Development or Management in Humans (R21 Clinical Trials Not Allowed)
NOFO Number: RFA-DE-22-011
Summary:

Temporomandibular joint (TMJ) disorders, which affect the joint connecting the lower jaw and the skull, are common and difficult chronic pain conditions. Pain management strategies that harness the body’s own pain relief mechanisms (including placebo effects in which pain relief cannot be attributed to a specific treatment), can reduce the severity and duration of TMJ-related chronic pain. Although research suggests that placebo effects may have a genetic basis, few, if any, genetic studies have examined this possibility in individuals with TMJ disorders. This project will use in-depth genetic, sociodemographic, clinical, and psychological data collected from adults with chronic TMJ disorders to better understand how the placebo effect works.
2R44DA051289-02
Wearable Sensor for Opioids Detection Based on Electrochemical Sensor Array Integrated with Bluetooth Device Cross-Cutting Research Small Business Programs NIDA EMITECH, INC. LEVITSKY, IGOR A Fall River, MA 2022
NOFO Title: HEAL Initiative: America’s Startups and Small Businesses Build Technologies to Stop the Opioid Crisis (R43/R44 - Clinical Trial Optional)
NOFO Number: RFA-DA-19-019
Summary:

This project will develop and refine a wearable device (forearm bracelet) designed to rapidly sense and report the presence of opioids in the wearer. This research will optimize this device to provide ultra-high sensitivity, enhanced drug specificity, long-term durability, low power consumption, and cost-effective production. The findings could support a path toward commercialization of this new device.